EA201991316A1 - Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту - Google Patents
Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислотуInfo
- Publication number
- EA201991316A1 EA201991316A1 EA201991316A EA201991316A EA201991316A1 EA 201991316 A1 EA201991316 A1 EA 201991316A1 EA 201991316 A EA201991316 A EA 201991316A EA 201991316 A EA201991316 A EA 201991316A EA 201991316 A1 EA201991316 A1 EA 201991316A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glp
- linker
- receptor agonist
- glucagon receptor
- hyaluronic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к конъюгату или его фармацевтически приемлемой соли, содержащим агонист рецептора GLP-1/глюкагона, линкер и гидрогель на основе гиалуроновой кислоты, несущей группы -L-L-L-Y-R, где Y представляет собой фрагмент агониста рецептора GLP-1/глюкагона; и при этом -L представляет собой линкерный фрагмент формулы (Ia)где пунктирная линия указывает на присоединение к одной из аминогрупп фрагмента агониста рецептора GLP-1/глюкагона посредством образования амидной связи. Настоящее изобретение дополнительно относится к фармацевтическим композициям, содержащим указанные конъюгаты, а также к их применению в качестве лекарственного препарата для лечения или предупреждения заболеваний или нарушений, которые можно лечить с помощью агониста рецептора GLP-1/глюкагона.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16306613 | 2016-12-02 | ||
PCT/EP2017/081217 WO2018100174A1 (en) | 2016-12-02 | 2017-12-01 | Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991316A1 true EA201991316A1 (ru) | 2019-10-31 |
Family
ID=57542941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991316A EA201991316A1 (ru) | 2016-12-02 | 2017-12-01 | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту |
Country Status (23)
Country | Link |
---|---|
US (2) | US10792367B2 (ru) |
EP (1) | EP3548090A1 (ru) |
JP (1) | JP2020503278A (ru) |
KR (1) | KR20190091482A (ru) |
CN (1) | CN110022902A (ru) |
AR (1) | AR110299A1 (ru) |
AU (1) | AU2017369723A1 (ru) |
BR (1) | BR112019011139A8 (ru) |
CA (1) | CA3045483A1 (ru) |
CL (1) | CL2019001466A1 (ru) |
CO (1) | CO2019006912A2 (ru) |
CR (1) | CR20190312A (ru) |
DO (1) | DOP2019000038A (ru) |
EA (1) | EA201991316A1 (ru) |
EC (1) | ECSP19046865A (ru) |
IL (1) | IL266973A (ru) |
MA (1) | MA46996A (ru) |
MX (1) | MX2019006432A (ru) |
PE (1) | PE20191472A1 (ru) |
PH (1) | PH12019501215A1 (ru) |
TW (1) | TW201832783A (ru) |
UY (1) | UY37505A (ru) |
WO (1) | WO2018100174A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
IL301616A (en) | 2016-03-01 | 2023-05-01 | Ascendis Pharma Bone Diseases As | PTH medications |
DK3518961T3 (da) | 2016-09-29 | 2023-04-24 | Ascendis Pharma Bone Diseases As | PTH-forbindelser med lave forhold mellem top og bund |
PL3518960T3 (pl) | 2016-09-29 | 2023-12-27 | Ascendis Pharma Bone Diseases A/S | Schemat dawkowania związku pth o kontrolowanym uwalnianiu |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
SG10202107829YA (en) | 2017-03-22 | 2021-08-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
TW201920240A (zh) | 2017-08-09 | 2019-06-01 | 法商賽諾菲公司 | 用於脂肪肝病和脂肪性肝炎治療的glp-1/胰高血糖素受體激動劑 |
TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物 |
FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
JP2023522364A (ja) | 2020-04-24 | 2023-05-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脂肪性肝疾患及び脂肪性肝炎の処置における長時間作用型glp-1受容体/グルカゴン受容体のアゴニストとしてのグルカゴン類似体 |
KR102225971B1 (ko) * | 2020-05-19 | 2021-03-10 | 주식회사 차메디텍 | 펩타이드 가교제를 이용한 히알루론산 기반의 하이드로겔 및 이의 제조 방법 |
CA3226846A1 (en) | 2021-07-30 | 2023-02-02 | Boehringer Ingelheim International Gmbh | Dose regimen for long-acting glp1/glucagon receptor agonists |
CN114470170B (zh) * | 2022-02-22 | 2023-09-19 | 广州新济药业科技有限公司 | 一种司美格鲁肽可溶性微针组合物及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2550718C (en) * | 2003-12-30 | 2013-11-05 | Genzyme Corporation | Cohesive gels from cross-linked hyaluronan and/or hylan, their preparation and use |
US8143391B2 (en) * | 2004-09-07 | 2012-03-27 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble hyaluronic acid modification |
BRPI0517341A (pt) | 2004-11-12 | 2008-10-07 | Novo Nordisk As | composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1 |
EP1817347B1 (en) * | 2004-11-24 | 2017-05-17 | Albumedix A/S | Method of cross-linking hyaluronic acid with divinylsulfone |
KR101349808B1 (ko) | 2005-06-13 | 2014-02-13 | 임페리얼 이노베이션스 리미티드 | 섭취행동에 관한 신규 화합물들 및 이들의 효능 |
EP1959986B1 (en) | 2005-11-07 | 2014-07-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US9353170B2 (en) | 2007-06-08 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
EP2217701B9 (en) | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon antagonists |
DK2237799T3 (da) | 2008-02-01 | 2019-06-11 | Ascendis Pharma As | Prodrug omfattende en selv-spaltbar linker |
SI2279007T1 (sl) | 2008-04-29 | 2016-09-30 | Ascendis Pharma Growth Disorders Division A/S | Spojine pegiliranega rekombinantnega humanega rastnega hormona |
PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
AU2008365555B2 (en) | 2008-12-15 | 2016-01-14 | Zealand Pharma A/S | Glucagon analogues |
EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
EP2459228B1 (en) | 2009-07-31 | 2020-03-04 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an insulin linker conjugate |
FR2952695B1 (fr) | 2009-11-13 | 2012-03-30 | Commissariat Energie Atomique | Reservoir de stockage d'hydrogene a hydrures metalliques |
PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JP6054861B2 (ja) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
NZ603169A (en) | 2010-04-27 | 2015-02-27 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
EP2578726B1 (en) | 2010-05-31 | 2018-10-17 | JTEKT Corporation | Method for manufacturing a coated member |
CN102906981B (zh) | 2010-06-01 | 2016-03-16 | 本田技研工业株式会社 | Dc/dc转换器的控制装置 |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
WO2012173422A1 (en) | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
AU2013284286A1 (en) | 2012-06-29 | 2015-02-05 | University Of South Australia | Fluid connection ports |
UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
KR20150096433A (ko) | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
WO2015086732A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080155A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US10188759B2 (en) * | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
AR105319A1 (es) * | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
-
2017
- 2017-11-30 AR ARP170103361A patent/AR110299A1/es unknown
- 2017-11-30 TW TW106141763A patent/TW201832783A/zh unknown
- 2017-12-01 US US15/829,596 patent/US10792367B2/en active Active
- 2017-12-01 MX MX2019006432A patent/MX2019006432A/es unknown
- 2017-12-01 WO PCT/EP2017/081217 patent/WO2018100174A1/en unknown
- 2017-12-01 KR KR1020197018576A patent/KR20190091482A/ko active Search and Examination
- 2017-12-01 JP JP2019529643A patent/JP2020503278A/ja not_active Abandoned
- 2017-12-01 CA CA3045483A patent/CA3045483A1/en not_active Abandoned
- 2017-12-01 AU AU2017369723A patent/AU2017369723A1/en not_active Abandoned
- 2017-12-01 EP EP17822168.5A patent/EP3548090A1/en active Pending
- 2017-12-01 MA MA046996A patent/MA46996A/fr unknown
- 2017-12-01 BR BR112019011139A patent/BR112019011139A8/pt not_active IP Right Cessation
- 2017-12-01 UY UY0001037505A patent/UY37505A/es not_active Application Discontinuation
- 2017-12-01 EA EA201991316A patent/EA201991316A1/ru unknown
- 2017-12-01 CR CR20190312A patent/CR20190312A/es unknown
- 2017-12-01 PE PE2019001081A patent/PE20191472A1/es unknown
- 2017-12-01 CN CN201780074647.0A patent/CN110022902A/zh active Pending
-
2019
- 2019-02-21 DO DO2019000038A patent/DOP2019000038A/es unknown
- 2019-05-29 IL IL266973A patent/IL266973A/en unknown
- 2019-05-30 CL CL2019001466A patent/CL2019001466A1/es unknown
- 2019-05-31 PH PH12019501215A patent/PH12019501215A1/en unknown
- 2019-06-27 CO CONC2019/0006912A patent/CO2019006912A2/es unknown
- 2019-07-01 EC ECSENADI201946865A patent/ECSP19046865A/es unknown
- 2019-10-28 US US16/665,785 patent/US11141489B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018100174A1 (en) | 2018-06-07 |
ECSP19046865A (es) | 2019-07-31 |
TW201832783A (zh) | 2018-09-16 |
AU2017369723A1 (en) | 2019-07-18 |
BR112019011139A8 (pt) | 2020-03-24 |
MX2019006432A (es) | 2019-08-21 |
AR110299A1 (es) | 2019-03-13 |
UY37505A (es) | 2018-06-29 |
US20200155688A1 (en) | 2020-05-21 |
DOP2019000038A (es) | 2019-05-31 |
KR20190091482A (ko) | 2019-08-06 |
IL266973A (en) | 2019-07-31 |
BR112019011139A2 (pt) | 2019-10-01 |
US10792367B2 (en) | 2020-10-06 |
JP2020503278A (ja) | 2020-01-30 |
CA3045483A1 (en) | 2018-06-07 |
US20180154005A1 (en) | 2018-06-07 |
CR20190312A (es) | 2019-09-11 |
CN110022902A (zh) | 2019-07-16 |
CL2019001466A1 (es) | 2019-10-11 |
PE20191472A1 (es) | 2019-10-16 |
MA46996A (fr) | 2019-10-09 |
PH12019501215A1 (en) | 2019-08-19 |
CO2019006912A2 (es) | 2020-04-24 |
EP3548090A1 (en) | 2019-10-09 |
US11141489B2 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
CY1122226T1 (el) | Προφαρμακα που περiλαμβανουν συζευγμα εξενδινης αρθρωτη | |
MX370141B (es) | Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón. | |
EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201500923A1 (ru) | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с | |
EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
EA201590697A1 (ru) | Производные кетамина | |
EA202191498A1 (ru) | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
EA201692300A1 (ru) | Производные карбоксамида | |
EA201891710A1 (ru) | Терапевтические соединения | |
EA201691160A1 (ru) | Антагонисты s1p3 | |
EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
EA201491651A1 (ru) | Новые соединения для лечения дислипидемии и родственных заболеваний | |
EA201691855A1 (ru) | Производные азаиндолуксусной кислоты и их применение в качестве модуляторов рецепторов простагландина d2 | |
EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
EA202190339A1 (ru) | Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов | |
BR112014000288A2 (pt) | moduladores do receptor de glucagon de quinolinila | |
EA201792170A1 (ru) | Производные индола |